Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
Related Experiment Video
Updated: Jul 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Esteban Martínez1, Juan A Arnaiz, Daniel Podzamczer
1Hospital Clínic, Barcelona, Spain.
Abstract:
Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

